Bristol-Myers Squibb Co vs Global X Robo Global Robotics & Automation ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Global X Robo Global Robotics & Automation ETF trades at $84.26. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| BMY | ROBO | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $90.34 |
52-Week Low | $42.60 | $62.34 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
ROBO, a US-listed robotics and automation ETF, trades at $84.76, up 1.56% today amid a bullish technical setup with strong moving average support. Key financial ratios are not disclosed for the ETF, but thematic focus on AI-driven robotics gains traction. Recent news highlights sector momentum and strategic rebalancing toward physical AI infrastructure.
Outlook remains positive given bullish technical signals and sector tailwinds, though high RSI suggests near-term overbought risk. Investors gain diversified exposure to robotics growth, but face volatility from cyclical end markets and valuation pressures as AI themes mature.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →